Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Activities of multiple cancer-related pathways are associated with BRAF mutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells.

Cell cycle (Georgetown, Tex.) - 1 Jan 2014

Liu Dingxie, Liu Xuan, Xing Mingzhao

Abstract excerpt

Drug resistance is a major obstacle in the targeted therapy of melanoma using BRAF/MEK inhibitors. This study was to identify BRAF V600E-associated oncogenic pathways that predict resistance of BRAF-mutated melanoma to BRAF/MEK inhibitors. We took in silico approaches to analyze the activities of 24 cancer-related pathways in melanoma cells and identify those whose activation was associated with BRAF V600E and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzimidazoles
Share to Cytokines
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Mitogen-Activated Protein Kinases

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to PTEN Phosphohydrolase

Source

Open in PubMed Open full text

Identifiers

PMID: 24200969
DOI: 10.4161/cc.26971
PMCID: PMC3906238

Genes

BRAF
EGFR
MYC
STAT3

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Activities of multiple cancer-related pathways are associated with BRAF mutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells.PMID 24200969Read ↗

Analysis of BRAF inhibitor resistance in melanoma cellsSemantic proximity Read ↗

A B-Raf V600E gene signature for melanoma predicts prognosis and reveals sensitivity to targeted therapies.Semantic proximity Read ↗

Microarray expression profiling in melanoma reveals a BRAF mutation signature.Semantic proximity Read ↗

Detecting mechanisms of acquired BRAF inhibitor resistance in melanoma.Semantic proximity Read ↗

Confirmation of a BRAF mutation-associated gene expression signature in melanoma.Semantic proximity Read ↗

Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.Semantic proximity Read ↗

Mitogen-Activated Protein Kinase Signaling Pathway in Cutaneous Melanoma: An Updated Review.Semantic proximity Read ↗

The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidenceSemantic proximity Read ↗

Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors.Semantic proximity Read ↗

Differential Gene Expression Common to Acquired and Intrinsic Resistance to BRAF Inhibitor Revealed by RNA-Seq AnalysisSemantic proximity Read ↗

BRAF and MEK inhibitor combinations induce potent molecular and immunological effects in NRAS-mutant melanoma cells: Insights into mode of action and resistance mechanisms.Semantic proximity Read ↗

Resistance to Targeted Therapy and RASSF1A Loss in Melanoma: What Are We Missing?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.